Total Funding
43
Total FundingSeed raised
Growth Score
pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
171036
BSIM Therapeutics is a biotech company to design of organ-targeted drug candidates for the treatment of transthyretin-mediated amyloidoses.
- Rui Brito: CEO
- Carlos Simões: CTO
About the Company
BSIM’s mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and related pathologies that represent important and unmet medical needs.
Our products are directed to a group of rare, hereditary and fatal pathologies commonly addressed to as
Transthyretin Amyloidoses (hATTR). We are developing drug candidates that fit within distinct target-product profiles for the treatment of a broader range of hATTR manifestations, including central nervous system symptoms (e.g. seizures, stroke-like events, progressive dementia) and oculopathy (e.g. vitreous opacities, glaucoma).
